Masimo Corp

Masimo CFO’s 26‑Feb 2026 PSU exercise shows stable insider liquidity, while FDA/EMA approvals and robust trial data confirm the company’s leadership in non‑invasive patient monitoring.

Masimo insider trading signals confidence in its non‑invasive tech, showing a strategic bet on value‑based care, RPM growth, and a potential upside despite legal hiccups.